Industry Experts

Sudhir Burman, Ph.D has been working in gene therapy development for more than 2 years.  He joined the University of Pennsylvania Gene Therapy program in 2023 and in late 2024 joined Gemma Biotherapeutics in King of Prussia, Pennsylvania. During his stay at Univ of Penn he was responsible for the CMC development of AAV based gene therapy products for First in Human clinical use.  Since joining Gemma his role has expanded to work toward late phase development towards licensure of these products. His work involves supporting different aspects of manufacturing, analytical troubleshooting and technology transfer to Contract Development and Manufacturing Organization (CDMO).

Prior to working in gene therapy product development, Sudhir has more than 30 years experience in biotech companies in early and late phase analytical development of recombinant monoclonal antibodies and other products.